Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes

Diabetic dyslipoproteinemia (DLP), characterized by quantitative, qualitative, and kinetic changes in all major circulating lipids, contributes to an increased risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (DM). Inhibition of proprotein convertase subtilisi...

Full description

Bibliographic Details
Main Authors: V.A. Serhiyenko, A.A. Serhiyenko
Format: Article
Language:English
Published: Zaslavsky O.Yu. 2023-03-01
Series:Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:
diabetes mellitus
proprotein convertase subtilisin/kexin type 9 inhibitors
review
Online Access:https://iej.zaslavsky.com.ua/index.php/journal/article/view/1242

Similar Items

Similar Items